Suppr超能文献

TLK1>Nek1轴促进YAP的核内滞留和激活,对去势抵抗性前列腺癌具有重要意义。

TLK1>Nek1 Axis Promotes Nuclear Retention and Activation of YAP with Implications for Castration-Resistant Prostate Cancer.

作者信息

Olatunde Damilola, De Benedetti Arrigo

机构信息

Department of Biochemistry and Molecular Biology, The Feist Weiller Cancer Center, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.

出版信息

Cancers (Basel). 2024 Aug 22;16(16):2918. doi: 10.3390/cancers16162918.

Abstract

Despite some advances in controlling the progression of prostate cancer (PCa) that is refractory to the use of ADT/ARSI, most patients eventually succumb to the disease, and there is a pressing need to understand the mechanisms that lead to the development of CRPC. A common mechanism is the ability to integrate AR signals from vanishing levels of testosterone, with the frequent participation of YAP as a co-activator, and pointing to the deregulation of the Hippo pathway as a major determinant. We have recently shown that YAP is post-transcriptionally activated via the TLK1>NEK1 axis by stabilizing phosphorylation at Y407. We are now solidifying this work by showing the following: (1) The phosphorylation of Y407 is critical for YAP retention/partition in the nuclei, and J54 (TLK1i) reverses this along with YAP-Y407 dephosphorylation. (2) The enhanced degradation of (cytoplasmic) YAP is increased by J54 counteracting its Enzalutamide-induced accumulation. (3) The basis for all these effects, including YAP nuclear retention, can be explained by the stronger association of pYAP-Y407 with its transcriptional co-activators, AR and TEAD1. (4) We demonstrate that ChIP for GFP-YAP-wt, but hardly for the GFP-YAP-Y407F mutant, at the promoters of typical ARE- and TEAD1-driven genes is readily detected but becomes displaced after treatment with J54. (5) While xenografts of LNCaP cells show rapid regression following treatment with ARSI+J54, in the VCaP model, driven by the oncogenic translocation, tumors initially respond well to the combination but subsequently recur, despite the continuous suppression of pNek1-T141 and pYAP-Y407. This suggests an alternative parallel pathway for CRPC progression for VCaP tumors in the long term, which may be separate from the observed ENZ-driven YAP deregulation, although clearly some YAP gene targets like PD-L1, that are found to accumulate following prolonged ENZ treatment, are still suppressed by the concomitant addition of J54.

摘要

尽管在控制对雄激素剥夺治疗(ADT)/雄激素受体抑制剂(ARSI)难治的前列腺癌(PCa)进展方面取得了一些进展,但大多数患者最终仍死于该疾病,因此迫切需要了解导致去势抵抗性前列腺癌(CRPC)发生发展的机制。一种常见机制是能够将来自睾酮水平消失的雄激素受体(AR)信号整合起来,YAP作为共激活因子频繁参与其中,这表明Hippo信号通路失调是一个主要决定因素。我们最近发现,YAP通过TLK1>NEK1轴在转录后被激活,即稳定Y407位点的磷酸化。我们现在通过以下研究来巩固这项工作:(1)Y407位点的磷酸化对于YAP在细胞核中的保留/分布至关重要,J54(TLK1抑制剂)通过使YAP - Y407去磷酸化来逆转这一过程。(2)J54通过抵消恩杂鲁胺诱导的(细胞质)YAP积累,增加了其降解。(3)所有这些效应的基础,包括YAP在细胞核中的保留,可以通过磷酸化的YAP - Y407与其转录共激活因子AR和TEAD1更强的结合来解释。(4)我们证明,在典型的雄激素反应元件(ARE)和TEAD1驱动基因的启动子处,GFP - YAP - wt的染色质免疫沉淀(ChIP)很容易检测到,但GFP - YAP - Y407F突变体几乎检测不到,而用J54处理后则被取代。(5)虽然LNCaP细胞异种移植瘤在用ARSI + J54治疗后迅速消退,但在由致癌易位驱动的VCaP模型中,肿瘤最初对联合治疗反应良好,但随后复发,尽管pNek1 - T141和pYAP - Y407持续受到抑制。这表明从长期来看,VCaP肿瘤的CRPC进展存在另一条平行途径,这可能与观察到的恩杂鲁胺驱动的YAP失调无关,尽管显然一些YAP基因靶点如程序性死亡配体1(PD - L1),在长期恩杂鲁胺治疗后被发现积累,但在同时添加J54后仍受到抑制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8809/11352418/75951cd3abee/cancers-16-02918-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验